The future of CTCL therapy

2 意见
administrator
administrator
08/09/23

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, shares her views on the future of cutaneous T-cell lymphoma (CTCL) therapy, highlighting the unmet need for more efficacious therapies and to determine the optimal sequencing of therapies. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

  • 类别

显示更多

0 注释 排序方式

没有找到评论

脸书评论

下一个